Pharma Stability: Insights, Guidelines, and Expertise
The FDA adopts the ICH Q1A(R2) guideline for stability testing of new drug substances and products. However, it may require additional details as per regional expectations. Key references include:
Click to read the full article.
The EMA follows ICH Q1A(R2) but tailors its stability storage conditions to the European climate. Most European countries fall under:
Click to read the full article.
The ASEAN Common Technical Dossier (ACTD) provides guidance for pharmaceutical submissions across ten Southeast Asian nations. These include:
Click to read the full article.
The TGA follows the ICH Q1B guideline for photostability testing, requiring both:
Click to read the full article.
Before submitting to regulatory agencies, conduct an internal QA review using this stability audit checklist:
Click to read the full article.
While both agencies expect a robust, ICH Q1A-compliant protocol, some subtle differences exist:
Click to read the full article.
Zone IVB represents a subset of the broader climatic zones used for stability studies. It is characterized by consistently high humidity and temperature, which can significantly impact the chemical and physical stability of pharmaceutical products.
Click to read the full article.
The starting point for protocol harmonization is the ICH Q1A(R2) guideline. Both FDA and EMA adhere to this for general principles of stability study design. Key shared elements include:
Click to read the full article.
Each region follows its own dossier format and technical requirements:
Click to read the full article.
One of the most frequent reasons for regulatory queries is the lack of clarity around packaging components. Regulators expect a precise description of:
Click to read the full article.